Virologists study the structure, replication, and behavior of viruses in order to understand and combat infectious diseases.
病毒学家研究病毒的结构、复制和行为，以期理解和对抗传染病。
The first step in virological research is isolating and identifying the virus from an infected host.
病毒学研究的第一步是从受感染宿主体内分离并鉴定病毒。
Influenza viruses mutate rapidly, making vaccine development a constant challenge for virologists.
流感病毒变异迅速，这给病毒学家的疫苗研发带来了持续的挑战。
Virologists use electron microscopes to visualize the intricate structures of viruses at the nanoscale.
病毒学家利用电子显微镜观察病毒在纳米尺度上的复杂结构。
Antiviral drugs target specific viral enzymes to inhibit their replication process.
抗病毒药物瞄准特定的病毒酶，以阻止其复制过程。
A vaccine is a key tool in
virology, preventing infection by stimulating the immune system to recognize and fight off viruses.
疫苗是病毒学中的关键工具，通过刺激免疫系统识别并抵抗病毒来预防感染。
The study of viral epidemiology helps track and predict the spread of diseases like COVID-19."
病毒流行病学的研究有助于追踪和预测像COVID-19这样的疾病的传播。
Virologists work on developing antiviral therapies for HIV, which has proven to be a persistent global health issue.
病毒学家致力于开发针对HIV的抗病毒疗法，这是全球公共卫生领域的一个持久挑战。
The virological concept of latency explains how some viruses can remain dormant within a host without causing symptoms.
潜伏性病毒概念解释了某些病毒如何能在宿主体内保持休眠状态而不引起症状。
Recent advances in
virology have led to the creation of gene therapy strategies targeting viral infections.
近期病毒学的进步推动了针对病毒感染的基因疗法策略的产生。
Gilead said it wanted to fully demonstrate innovative products in virology, oncology and other disease areas, as well as the innovative technologies behind many of its star products.
吉利德表示，希望充分展示病毒学、肿瘤学和其他疾病领域的创新产品，以及其许多明星产品背后的创新技术。
Those Gilead innovative medicines that are available in China across virology, oncology and fungal infections will also be presented at CIIE.
吉利德在中国提供的病毒学、肿瘤学和真菌感染方面的创新药物也将在CIIE上展出。
"Thanks to the healthcare policies in China, Gilead Sciences has been growing rapidly in the country with 11 drugs approved over the past few years, addressing unmet medical needs in virology, oncology and invasive fungal disease… China is one of Gilead's key strategic markets, and we have a long-term commitment to patients in China and strong confidence in our long-term development here," said Jin Fangqian, vice president of Gilead Sciences and general manager of its China arm.
他说：“得益于中国的医疗政策，吉利德科学公司在中国迅速发展，在过去几年里批准了11种药物，解决了病毒学、肿瘤学和侵袭性真菌疾病方面未满足的医疗需求……中国是吉利德的关键战略市场之一，我们对中国的患者有着长期的承诺，并对我们在中国的长期发展充满信心。”金方谦，吉利德科学公司副总裁兼中国分公司总经理。
The fifth China International Import Expo, kicking off on Saturday, is offering great opportunities for internationally leading pharmaceutical company Gilead Sciences to showcase its new discoveries in virology, oncology and mycology sciences, the company said.
吉利德公司表示，将于周六开幕的第五届中国国际进口博览会为国际领先的制药公司吉利德科学公司展示其在病毒学、肿瘤学和真菌学科学领域的新发现提供了绝佳机会。
The vaccine was co-developed by the Wuhan Institute of Biological Products and the Wuhan Institute of Virology under the Chinese Academy of Sciences.
On April 24, CNBG launched phase-2 human trials of its first inactivated vaccine, which was codeveloped by the Wuhan Institute of Biological Products and the Wuhan Institute of Virology under the Chinese Academy of Sciences.
On Friday, CNBG launched phase-2 human trials of its first inactivated vaccine, which is codeveloped by its unit, the Wuhan Institute of Biological Products, along with the Wuhan Institute of Virology under the Chinese Academy of Sciences.
上周五，中国生物集团启动了其首款灭活疫苗的二期人体临床试验，该疫苗由其下属的武汉生物制品研究所与隶属于中国科学院的武汉病毒研究所共同研发。
The vaccine, co-developed by the company's subsidiary, China National Biotech Group Co Ltd, and the Wuhan Institute of Virology under the Chinese Academy of Science, was the first inactivated vaccine against the novel coronavirus approved for clinical trials globally, the company said, which also is known as China National Pharmaceutical Group Co.
In addition, two antibody detection kits jointly developed by Wuhan Institute of Virology and a pharmaceutical company have started production and will soon be put into the market.
On Jan 28, the COVID-19 oral medicine jointly developed by Nanjing-based Simcere Pharmaceutical Group Ltd and two institutes under the Chinese Academy of Sciences — the Shanghai Institute of Materia Medica and the Wuhan Institute of Virology — was approved by the National Medical Products Administration for "treating mild to moderate adult COVID-19 patients".
On April 24, CNBG launched phase-2 human trials of its first inactivated vaccine, which is codeveloped by the Wuhan Institute of Biological Products and the Wuhan Institute of Virology under the Chinese Academy of Sciences.
未经许可，严禁转发。QQ交流群：688169419